Program
Memantine
Also written as “Memantine Hydrochloride (HCl)”, “memantine” and “memantine HCl”.
Its studies are mostly in Alzheimer Disease · Autistic Disorder · Autism Spectrum Disorder · Glaucoma, Open-Angle · Cancer Pain, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 130 open or running | phase 4since Jun 6, 2006 | Dec 1, 2004 | none ahead |
| H. Lundbeck | 60 open or running | phase 4since Mar 3, 2009 | Mar 3, 2009 | none ahead |
| Merz Pharma | 40 open or running | phase 4since Mar 27, 2008 | Feb 14, 2008 | none ahead |
| Carnot Laboratories | 10 open or running | phase 4since Feb 11, 2026 | Feb 11, 2026 | none ahead |
| Gedeon Richter Plc. | 10 open or running | phase 1since Nov 15, 2013 | Nov 15, 2013 | none ahead |
| Geropharm | 10 open or running | phase 1since Apr 18, 2017 | Apr 18, 2017 | none ahead |
| Mendel AI | 10 open or running | phase 3since Jan 30, 2021 | Jan 30, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 9 studies since Dec 1, 2004.
- Mar 27, 2008Phase 4 study in Alzheimer DiseaseMerz Pharma · NCT00649220 · 19 enrolled · Germany
- Dec 5, 2008Phase 3 study in Alzheimer DiseaseMerz Pharma · NCT00804271 · 487 enrolled · Germany
- Mar 3, 2009H. Lundbeck's first studies: 2 phase 4 studiesNew to H. LundbeckH. Lundbeck · NCT00855686, NCT00862940
- Mar 5, 20092 phase 3 studies in Alzheimer DiseaseH. Lundbeck · NCT00857649, NCT00857233
- Mar 30, 2009Phase 2 study in Autistic DisorderAbbVie · NCT00872898 · 124 enrolled · United States
- Dec 15, 2010Phase 2 study in Memory DisordersMerz Pharma · NCT01261741 · 299 enrolled · Germany, United Kingdom
- May 3, 20123 phase 2 studiesAbbVie · NCT01592786, NCT01592773, NCT01592747
- Nov 15, 2013Gedeon Richter Plc.'s first study: phase 1 study in ObesityNew to Gedeon Richter Plc.Gedeon Richter Plc. · NCT02001584 · United Kingdom
- Nov 26, 2013Phase 2 study in Autistic DisorderAbbVie · NCT01999894 · 102 enrolled · United States
- Sep 16, 2015Phase 4 study in Alzheimer DiseaseH. Lundbeck · NCT02553928 · 62 enrolled · China
- Apr 18, 2017Geropharm's first study: phase 1 study in Bioequivalence, AUC, Cmax, PharmacokineticsNew to GeropharmGeropharm · NCT03121820 · 18 enrolled · Russian Federation
- Sep 12, 2018Phase 1 study in HealthyH. Lundbeck · NCT03670095 · 64 enrolled · China
- Jan 30, 2021Mendel AI's first study: phase 3 study in Cancer PainNew to Mendel AIMendel AI · NCT04737967 · 60 enrolled · Egypt
- Feb 11, 2026Carnot Laboratories's first study: phase 4 study in Alzheimer DiseaseNew to Carnot LaboratoriesCarnot Laboratories · NCT07417670 · 105 enrolled · Mexico
TargetBeta
“Glutamate [NMDA] receptor negative allosteric modulator”ChEMBL 37, by rule
Other programs on the same 7 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Esketaminerule | Johnson & Johnson | phase 4 | 51 |
Studies
All 27 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07417670Alzheimer Disease · Mexico | 4 | Completed | Carnot Laboratories | Aug 12, 2025 | 105 |
| NCT04737967Cancer Pain · Egypt | 3 | UNKNOWN | Mendel AI | Aug 15, 2021 | 60 |
| NCT03670095Healthy · China | 1 | Completed | H. Lundbeck | Dec 24, 2018 | 64 |
| NCT03121820Bioequivalence, AUC, Cmax, Pharmacokinetics · Russian Federation | 1 | Completed | Geropharm | Nov 19, 2016 | 18 |
| NCT02553928Alzheimer Disease · China | 4 | Completed | H. Lundbeck | Jul 2016 | 62 |
| NCT01999894Autistic Disorder · United States | 2 | Completed | AbbVie | Feb 2013 | 102 |
| NCT02001584Obesity · United Kingdom | 1 | Completed | Gedeon Richter Plc. | May 2014 | |
| NCT01592786Autism Spectrum Disorder · United States, Australia, Belgium and more | 2 | Completed | AbbVie | Jul 2013 | 906 |
| NCT01592773Autism Spectrum Disorder · United States, Belgium, Canada and more | 2 | Terminated | AbbVie | Jan 2014 | 747 |
| NCT01592747Autistic Disorder · United States, Belgium, Colombia and more | 2 | Completed | AbbVie | Sep 2013 | 479 |
| NCT01261741Memory Disorders · Germany, United Kingdom | 2 | Completed | Merz Pharma | Aug 2011 | 299 |
| NCT00872898Autistic Disorder · United States | 2 | Completed | AbbVie | Aug 2012 | 124 |
| NCT00862940Alzheimer Disease | 4 | Completed | H. Lundbeck | Feb 2009 | 277 |
| NCT00857649Alzheimer Disease · Canada | 3 | Terminated | H. Lundbeck | Apr 2010 | 369 |
| NCT00857233Alzheimer Disease · Canada | 3 | Terminated | H. Lundbeck | Jul 2010 | 297 |
| NCT00855686Lewy Body Disease · Germany | 4 | Completed | H. Lundbeck | Dec 2008 | 199 |
| NCT00804271Alzheimer Disease · Germany | 3 | Completed | Merz Pharma | Nov 2009 | 487 |
| NCT00649220Alzheimer Disease · Germany | 4 | Terminated | Merz Pharma | May 2009 | 19 |
| NCT00624026Alzheimer Disease · Germany | 3 | Completed | Merz Pharma | Dec 2008 | 107 |
| NCT00469456Alzheimer Disease · Australia, New Zealand, South Africa | 4 | Completed | AbbVie | Nov 2008 | 265 |
| NCT00334906Alzheimer Disease · United States | 4 | Completed | AbbVie | Nov 2007 | 75 |
| NCT00322153Alzheimer Disease · United States, Argentina, Chile and more | 3 | Completed | AbbVie | Oct 2007 | 677 |
| NCT00168350Glaucoma, Open-Angle | 3 | Completed | AbbVie | Sep 2006 | 1,179 |
| NCT00141882Glaucoma, Open-Angle | 3 | Completed | AbbVie | Jan 2006 | 1,119 |
| NCT00106405Bipolar Disorder · United States | 2 | Completed | AbbVie | Nov 2005 | 35 |
| NCT00097942Schizophrenia · United States | 2 | Completed | AbbVie | Sep 2005 | 138 |
| NCT00097916Alzheimer Disease · United States | 3 | Completed | AbbVie | Apr 2006 | 34 |
How it is read
Names in the registry
- “Memantine”, 11 entries
- “Memantine Hydrochloride (HCl)”, 4 entries
- “memantine”, 3 entries
- “memantine HCl”, 3 entries
- “Memantine HCl”, 2 entries
Conditions, from the studies’ own filings
- Alzheimer Disease, 14 studies
- Autistic Disorder, 3 studies
- Autism Spectrum Disorder, 2 studies
- Glaucoma, Open-Angle, 2 studies
- Cancer Pain, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.